Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors from the central nervous process, conolidine modulates alternate molecular targets. A Science Developments review discovered that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://juliann791pii8.ziblogs.com/profile